首页> 外文期刊>Journal of vascular and interventional radiology: JVIR >Perivascular release of insulin-like growth factor-1 limits neointima formation in the balloon-injured artery by redirecting smooth muscle cell migration.
【24h】

Perivascular release of insulin-like growth factor-1 limits neointima formation in the balloon-injured artery by redirecting smooth muscle cell migration.

机译:胰岛素样生长因子-1的血管周围释放通过重定向平滑肌细胞迁移来限制球囊损伤动脉中的新内膜形成。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: Insulin-like growth factor-1 (IGF-1) is a potent chemoattractant to vascular smooth muscle cells (SMCs). The authors hypothesize that perivascular release of IGF-1 in vivo can direct migration of SMCs away from the lumen and reduce neointima formation in a rabbit model of arterial balloon injury. MATERIALS AND METHODS: Balloon angioplasty of the common femoral arteries was performed in adult male New Zealand White rabbits (n = 8 per treatment group) and controlled release microspheres delivering either IGF-1 or blank control treatment were implanted perivascularly at the angioplasty site prior to surgical closure. At 7 days, five arteries per group were harvested and cross-sections were subjected to anti-PCNA (proliferating cell nuclear antigen) immunostaining to determine the number and distribution of proliferating SMCs. At 28 days, the remaining three arteries per group were harvested and sections were evaluated for intima-to-media (I/M) ratios by means of VVG-Masson staining. One-way analysis of variance with Fisher protected least significant difference post hoc testing was used to determine statistical significance at P < .05. RESULTS: At 7 days, PCNA(+) medial SMCs assumed a significantly more peripheral (ie, further from lumen) distribution in the vessel wall with use of perivascular IGF-1 than with use of blank treatment (P < .05). Overall SMC proliferation was not significantly different, thus the change in distribution was likely due to directionally altered SMC migration. At 28 days, perivascular IGF-1 significantly decreased I/M ratios by 44% relative to control treatment (P < .05). CONCLUSIONS: Perivascular release of IGF-1 can directionally guide SMC migration away from the lumen and reduce neointima in the balloon-injured artery. This novel strategy might have implications in the development of antirestenosis therapies.
机译:目的:胰岛素样生长因子-1(IGF-1)是血管平滑肌细胞(SMCs)的有效化学引诱剂。作者假设,体内IGF-1的血管周围释放可以指导SMC从腔中迁移出来,并减少兔子球囊损伤模型中新内膜的形成。材料与方法:在成年雄性新西兰白兔中进行普通股动脉的球囊血管成形术(每个治疗组n = 8),并在血管成形术部位在血管周围植入可释放IGF-1或空白对照治疗的控释微球。手术关闭。在第7天,每组收获5条动脉,并对横截面进行抗PCNA(增殖细胞核抗原)免疫染色,以确定增殖的SMC的数量和分布。在第28天,收获每组剩余的三个动脉,并通过VVG-Masson染色评估切片的内膜对中膜(I / M)比。事后检验采用费舍尔保护的最小显着差异的单向方差分析确定P <.05时的统计显着性。结果:在第7天,使用血管周围IGF-1的PCNA(+)内侧SMC的血管壁周围(即距管腔较远)的分布明显比空白治疗高(P <.05)。总体SMC增殖没有显着差异,因此分布的变化很可能是由于SMC迁移的方向改变所致。在第28天时,相对于对照治疗,血管周围IGF-1使I / M比值显着降低了44%(P <.05)。结论:IGF-1的血管周围释放可以指导SMC从管腔迁移,并减少球囊损伤动脉的新内膜。这种新颖的策略可能对抗再狭窄疗法的发展产生影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号